Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT03753633
What this trial is testing

Efficiency of Speech Therapy in Resistant Hypertensive Patients With Mild Obstructive Sleep Apnea Syndrome

Who this might be right for
Sleep Apnea, ObstructiveHypertension Secondary
Universidade Federal do Rio de Janeiro 50
Testing effectiveness (Phase 2)UnknownNCT04603833
What this trial is testing

SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Who this might be right for
Prostate Cancer Metastatic
Jiangsu HengRui Medicine Co., Ltd. 150
Testing effectiveness (Phase 2)Study completedNCT01080352
What this trial is testing

Vitamin C as an Anti-cancer Drug

Who this might be right for
Prostatic Neoplasms
Copenhagen University Hospital at Herlev 31
Not applicableLooking for participantsNCT07093801
What this trial is testing

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03319628
What this trial is testing

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Who this might be right for
Platinum Resistant Ovarian CancerNon Small Cell Lung Cancer Metastatic
Mersana Therapeutics 523
Testing effectiveness (Phase 2)Ended earlyNCT02933801
What this trial is testing

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Who this might be right for
Prostate Cancer MetastaticProstate Cancer
Swiss Cancer Institute 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT04777071
What this trial is testing

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Who this might be right for
Biochemically Recurrent Prostate CarcinomaMetastatic Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma+3 more
University of Washington 141
Testing effectiveness (Phase 2)Study completedNCT04158245
What this trial is testing

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tulane University 9
Early research (Phase 1)Study completedNCT00872157
What this trial is testing

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 10
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Not applicableStudy completedNCT02551263
What this trial is testing

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 201
Early research (Phase 1)Looking for participantsNCT05283330
What this trial is testing

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Who this might be right for
Cervical CancerBreast CancerColon Cancer+4 more
Orano Med Theranostics, SAS 48
Testing effectiveness (Phase 2)Ended earlyNCT01089595
What this trial is testing

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Who this might be right for
GISTMetastatic Disease
Fox Chase Cancer Center 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301
What this trial is testing

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Who this might be right for
Small Cell Lung Cancer Extensive StageResistance to Immunotherapy
First Affiliated Hospital of Wannan Medical College 25
Testing effectiveness (Phase 2)WithdrawnNCT02793219
What this trial is testing

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
The University of Texas Health Science Center, Houston
Testing effectiveness (Phase 2)Active Not RecruitingNCT04015622
What this trial is testing

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
British Columbia Cancer Agency 100
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Testing effectiveness (Phase 2)Looking for participantsNCT07698535
What this trial is testing

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Who this might be right for
Metastatic Castration-Resistant Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
University of Washington 64
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395079
What this trial is testing

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Who this might be right for
Metastatic Malignant Female Reproductive System NeoplasmPlatinum-Resistant Malignant Female Reproductive System NeoplasmRecurrent Malignant Female Reproductive System Neoplasm+1 more
Jonsson Comprehensive Cancer Center
Next Page
9